- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07665281
Impact of Hyaluronic Acid and Bone Graft on Peri-Implant Tissue
Impact of Hyaluronic Acid and Bone Graft on PeriImplant Tissue Phenotype."A Randomized Controlled Trial"
This randomized controlled clinical trial aims to evaluate the effect of hyaluronic acid (HA) and particulate bone graft on the peri-implant tissue phenotype in patients receiving dental implants. Healthy adult participants requiring dental implant placement will be randomly allocated into one of three equal groups (12 implants per group): Group 1 will receive dental implants combined with hyaluronic acid gel (Gengigel); Group 2 will receive dental implants combined with both hyaluronic acid and particulate bone graft; and the control group will receive dental implants alone.
Clinical and radiographic assessments will be performed using a customized measurement stent to ensure standardized evaluations at baseline, immediately postoperatively, and at 8 and 16 weeks of follow-up. The primary and secondary outcomes include alterations in ridge width, keratinized tissue width/thickness, radiographic soft tissue height, and marginal bone height. The study aims to determine whether the adjunctive use of hyaluronic acid and bone grafts enhances the quality of the peri-implant soft and hard tissue phenotype.
Studieoversikt
Status
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Babylon
-
Hillah, Babylon, Irak
- College of Dentistry, University of Babylon
-
Hillah, Babylon, Irak
- Private specialized dental center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Adults ≥ 18 years old.
- Partially edentulous patients requiring dental implant placement.
- Good oral hygiene (Calibrated Gingival Bleeding Index (GBI) < 10%, O'Leary ---Plaque Index (PI) < 10%).
- Sufficient bone volume for implant placement.
Exclusion Criteria:
- Systemic conditions affecting bone healing (e.g., uncontrolled diabetes).
- Smoking > 10 cigarettes/day.
- Medications affecting bone metabolism (e.g., bisphosphonates).
- Active periodontal disease.
- Pregnant or lactating women.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group 1: Dental Implants + Hyaluronic Acid
Patients receive dental implants combined with hyaluronic acid gel applied at the implant site.
|
Surgical placement of dental implants, followed by the application of hyaluronic acid gel at the implant site, was performed to evaluate its impact on peri-implant tissue phenotype.
|
|
Eksperimentell: Group 2: Dental Implants + Hyaluronic Acid + Bone Graft
Patients receive dental implants combined with hyaluronic acid gel and particulate bone graft applied at the implant site.
|
Surgical placement of dental implants, combined with the application of hyaluronic acid gel and particulate bone graft at the implant site, was performed to evaluate its impact on peri-implant tissue phenotype.
|
|
Aktiv komparator: Group 3: Control Group: Dental Implants Alone
Patients receive standard dental implants placement alone without any adjunctive materials.
|
Standard surgical placement of dental implants following conventional clinical protocols without the application of any adjunctive materials.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Ridge Width Changes (RW)
Tidsramme: Baseline (preoperative), immediate postoperative, 8 weeks, and 16 weeks.
|
The changes in Ridge Width is measured at the reference points using a digital vernier caliper.
|
Baseline (preoperative), immediate postoperative, 8 weeks, and 16 weeks.
|
|
Bone Width (BW)
Tidsramme: Baseline (preoperative), and 16 weeks postoperatively
|
Measured in millimeters by subtracting the buccal and lingual mucosal thickness from the ridge width.
|
Baseline (preoperative), and 16 weeks postoperatively
|
|
Change in width of keratinized tissue (KTW)
Tidsramme: Baseline (preoperative), 8 weeks, and 16 weeks
|
Measured in millimeters at the mid-buccal aspect of the implant site using an endodontic rotary file and digital vernier caliper.
|
Baseline (preoperative), 8 weeks, and 16 weeks
|
|
Keratinized Tissue Thickness (KTT)
Tidsramme: Baseline (preoperative), and 16 weeks postoperatively
|
Measured in millimeters at the buccal, crestal and lingual reference points using a periodontal probe and a digital vernier caliper.
|
Baseline (preoperative), and 16 weeks postoperatively
|
|
Radiographic Mucosal Thickness (RT)
Tidsramme: Baseline (preoperative), immediate postoperative, 8 weeks, and 16 weeks
|
Measured in millimeters on periapical radiographs using digital software from the crestal bone level to the crest of crestal oral mucosa 5 mm away from the height distal surface of the adjacent tooth on the mesial side of the implant.
|
Baseline (preoperative), immediate postoperative, 8 weeks, and 16 weeks
|
|
Crestal Bone Height (BH)
Tidsramme: Immediate postoperative, 8 weeks, and 16 weeks
|
Measured in millimeters on periapical radiographs using digital software from the second serration on the mesial side of the implant to the crest of the bone.
|
Immediate postoperative, 8 weeks, and 16 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Plaque Index (PI)
Tidsramme: Baseline (preoperative), 8 weeks, and 16 weeks
|
O'Leary plaque index
|
Baseline (preoperative), 8 weeks, and 16 weeks
|
|
Gingival Index (GI)
Tidsramme: Baseline (preoperative), 8 weeks, and 16 weeks
|
Gingival Bleeding Index
|
Baseline (preoperative), 8 weeks, and 16 weeks
|
|
Postoperative Pain Scores
Tidsramme: Three times daily (morning, afternoon, and evening) for the first 7 days postoperatively
|
Patients received a standardized pain assessment chart for self-evaluation over seven consecutive postoperative days.
This chart featured an 11-point (0-10) Numerical Rating Scale (NRS) integrated with the Wong-Baker Faces Pain Rating Scale and supplemented with descriptive pain expressions ranging from a minimum value of 0 (representing no pain) to a maximum value of 10 (representing the worst possible pain), where higher scores indicate a worse outcome (greater pain severity).
|
Three times daily (morning, afternoon, and evening) for the first 7 days postoperatively
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Beinresorpsjon
- Beinsykdommer
- Muskel- og skjelettsykdommer
- Periodontal atrofi
- Periodontale sykdommer
- Munnsykdommer
- Stomatognatiske sykdommer
- Kjevesykdommer
- Tannsykdommer
- Munn, edentuous
- Jaw, edentuous
- Alveolært bentap
- Kjeve, edentuous, delvis
- Karbohydrater
- Utstyr og forsyninger
- Biomedisinske og tannlegematerialer
- Produsert materiale
- Teknologi, industri og landbruk
- Glykosaminoglykaner
- Polysakkarider
- Proteser og implantater
- Tannbehandling
- Tannmaterialer
- Tannprotese
- Protodonti
- Hyaluronsyre
- Tannimplantater
Andre studie-ID-numre
- MUOSU/POST-202615
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .